[Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
Experimental administration of the CMF scheme, which is used in adjuvant chemotherapy in humans, resulted in carcinogenic effects in rats. When substituting cyclophosphamide by vincristine, no carcinogenic activity was observed. The therapeutic effect of the VMF scheme was approximately equivalent to that of the CMF scheme in various experimental designs. It is discussed whether in adjuvant chemotherapy combinations should rather be used which lack any long-term toxicity such as carcinogenic effects.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000633:toxicity; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000633:toxicity; D008770:Methylnitrosourea; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000139:chemically induced; D051381:Rats; D011919:Rats, Inbred Strains; D012517:Sarcoma, Yoshida / Q000188:drug therapy; D014750:Vincristine / Q000008:administration & dosage / Q000633:toxicity
D014750:Vincristine; D008770:Methylnitrosourea; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Experimentelle toxikologische und therapeutische Untersuchungen zur Wirkung des CMF-(Cyclophosphamid-Methotrexat-5-Fluorouracil)-Schemas gegenüber dem VMF-(Vincristin-Methotrexat-5-Fluorouracil)-Schema.